KENALOG IN ORABASE Drug Patent Profile
✉ Email this page to a colleague
When do Kenalog In Orabase patents expire, and what generic alternatives are available?
Kenalog In Orabase is a drug marketed by Delcor Asset Corp and is included in one NDA.
The generic ingredient in KENALOG IN ORABASE is triamcinolone acetonide. There are fifty-one drug master file entries for this compound. Sixty-nine suppliers are listed for this compound. Additional details are available on the triamcinolone acetonide profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Kenalog In Orabase
A generic version of KENALOG IN ORABASE was approved as triamcinolone acetonide by TARO on October 1st, 1986.
Summary for KENALOG IN ORABASE
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 82 |
Clinical Trials: | 1 |
Patent Applications: | 4,306 |
Formulation / Manufacturing: | see details |
DailyMed Link: | KENALOG IN ORABASE at DailyMed |
Recent Clinical Trials for KENALOG IN ORABASE
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Cairo University | Phase 3 |
Anatomical Therapeutic Chemical (ATC) Classes for KENALOG IN ORABASE
US Patents and Regulatory Information for KENALOG IN ORABASE
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Delcor Asset Corp | KENALOG IN ORABASE | triamcinolone acetonide | PASTE;DENTAL | 012097-001 | Approved Prior to Jan 1, 1982 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |